Corvus Pharmaceuticals Inc

NASDAQ:CRVS  
4.03
+0.13 (+3.33%)
Products, Regulatory

Corvus Completes Enrollment In Phase 1 Study Of Cpi-006 For Patients With COVID-19

Published: 11/09/2020 14:36 GMT
Corvus Pharmaceuticals Inc (CRVS) - Corvus Completes Enrollment in Phase 1 Study of Cpi-006 for Patients With Covid-19.
Corvus Pharmaceuticals - Data Shows Cpi-006 Provided Enhanced and Prolonged Polyclonal Humoral Immunity to Sars-cov-2.
Corvus Pharmaceuticals - Plans to Initiate Pivotal, Randomized, Double Blind Trial in December With Results Expected Mid-2021.